Botulinum toxin type A for the treatment of patients with post-stroke spasticity in Thailand: cost-utility and budget impact analysis.

ABSTRACT:

Objectives

To evaluate the cost-utility of botulinum toxin A (BoNT-A) for treating upper limb (UL) and lower limb (LL) post-stroke spasticity.

Design

Using a Markov model, adopting a societal perspective and a lifetime horizon with a 3% annual discount rate, the cost-utility analysis was conducted to compare BoNT-A combined with standard of care (SoC) with SoC alone. Costs, utilities, transitional probabilities and treatment efficacy were derived from 5-year retrospective data from tertiary hospitals and meta-analysis. Uncertainty analyses were performed.

Setting

Tertiary hospitals in Thailand.

Participants

Cohort of post-stroke patients aged 55 years with UL or LL spasticity and a Modified Ashworth Scale score ≥1+.

Interventions

BoNT-A (abobotulinumtoxi

SUBMITTER: Hadnorntun P 

PROVIDER: S-EPMC11749450 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature